相关实验视频

Updated: Jul 9, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

托法西替尼在治疗多关节性病程青少年异常性关节炎时的安全性和有效性

Nicholas T Jones¹, Camryn L Keller¹, Raegan B Abadie¹

¹School of Medicine, Louisiana State University Health Sciences Center, Shreveport, USA.

|December 6, 2023

概括

托法西替尼 (tofacitinib) 显示出治疗多关节过程青少年异常性关节炎 (pcJIA) 的前景,为对传统治疗不耐药的患者提供潜在的益处. 需要进一步的儿科试验来确认在年轻人群中有效性和安全性.

科学领域:

类风湿病学类风湿病学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

多关节性青年形态性关节炎 (pcJIA) 在16岁以下的个体中影响至少五个关节.
常见的症状包括疼痛,胀和运动能力受限,严重影响日常生活.
传统的治疗方法如NSAIDs和DMARDs由于副作用和在某些情况下的无效性而存在局限性.

研究的目的:

进行托法西提尼布作为PCJIA的新疗法的风险效益分析.
评估托法西提尼布在控制PCJIA症状和改善患者治疗结果方面的潜力.

主要方法:

审查现有的文献和有关托法西提尼布疗效和安全性资料的数据.
对托法西提尼布 (tofacitinib) 的JAK/STAT通路抑制机制的分析.
风险-益处评估重点关注副作用和治疗潜力.

主要成果:

在审查的数据中,托法西提尼布表现出相对较轻的副作用概况.
严重的不良事件主要观察到免疫功能低下或代谢障碍的个体.
在免疫能力强的pcJIA患者中,注意到降低发作和红细胞沉率 (ESR) 的潜在有效性.

结论:

托法西提尼布为pcJIA提供了潜在的替代治疗方法,特别是对于那些对传统疗法没有反应的患者.
该药物可能有效地控制pcJIA症状和炎症标志物.
进一步的大规模临床试验对于验证托法西提尼布在儿科患者群体中的安全性和有效性至关重要.

关键词:

关节炎是一种关节炎.有效性有效性有效性.多关节过程青少年异常性关节炎在安全方面,安全是安全的.托法西提尼布 (tofacitinib) 是一种

更多相关视频

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...